A single company owns the exclusive patent on the BRCA 1 and 2 mutations—and jacks up the price for a $200 genetic test for breast cancer risk to $3,000, just because they can.:
In the wake of Angelina Jolie’s well-intention exhortation for “every woman” to explore their risk of breast cancer, one company stands to make a staggering profit.